Author Archives: Patricia Silva PhD

Occlutech’s atrial flow regulator (AFR) — a cardiac implant — received breakthrough device designation from the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH). Breakthrough status is given to medical equipment that offer significant advantages over currently available options for the treatment of…

Roivant recently announced the launch of two new business units, Roivant Pharma and Roivant Health, as well as the creation of Altavant Sciences, a company that will focus on developing new therapies, including RVT-1201 as a potential treatment for pulmonary arterial hypertension (PAH). As part of its long-term strategy, Roivant…

Denovo Biopharma recently entered an exclusive global license agreement with Stanford University School of Medicine to further develop and market its lead compound, DB102 (formerly called enzastaurin), as a potential treatment for pulmonary arterial hypertension (PAH) and emphysema. In research in preclinical models at Stanford, DB102 was found…

The non-profit Team PHenomenal Hope is helping Puerto Ricans with pulmonary hypertension (PH) during the ongoing power outage crisis by providing portable solar panels and battery packs. The power outage was caused by Hurricane Maria, in September 2017, which inflicted significant damage to the island. Recovery wasn’t easy…

Credit: phaware Every year, World PH Day is celebrated on May 5. This year the virtual non-profit #phaware global association is inviting friends of the pulmonary hypertension (PH) community to become a #phaware brand ambassador and participate in activities worldwide to raise awareness of the…

The University of Virginia’s (UVA) Pulmonary Hypertension Center has been recognized as a Center of Comprehensive Care by the Pulmonary Hypertension Association (PHA). The PHA-accredited PH Care Centers initiative aims to establish an accreditation program for centers with special expertise in pulmonary hypertension (PH), particularly pulmonary arterial hypertension…

Cardiome recently shared an update on the development of its therapeutic portfolio, including Trevyent (treprostinil injection) for the treatment of pulmonary arterial hypertension (PAH). Following the U.S. Food and Drug Administration’s (FDA) refusal last year to approve a new drug application (NDA) submitted by Trevyent’s licensor SteadyMed,…

An Ochsner Health System facility in New Orleans has received Pulmonary Hypertension Association  care center accreditation. The association accredits care centers that can assure patients receive top PH diagnosis and treatment. Ochsner’s PH program is located at the John Ochsner Heart and Vascular Institute. It is one of only two accredited…

The NYU Langone Transplant Institute recently launched a new lung transplant program to offer lung disease patients in the New York City area an array of comprehensive services. The lung transplant program is the third of its kind in the New York area. It offers patients with…

Liquidia Technologies has started a Phase 3 clinical trial to evaluate LIQ861 as a treatment for pulmonary arterial hypertension. LIQ861 is a dry-powder, inhaled formulation of treprostinil that Liquidia developed to deliver deep into the lungs. U.S. regulators have already approved other formulations of treprostinil, which is a synthetic version…

Bellerophon Therapeutics has enrolled the first patient in a Phase 2b clinical trial evaluating INOpulse as a treatment for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The trial (NCT03267108) will assess the safety and effectiveness of Bellerophon’s pulsed, inhaled nitric oxide treatment for people with PH-ILD, including…

A report about life with pulmonary arterial hypertension (PAH) as a young person, created by young patients worldwide, addresses issues both pertinent and challenging to this age group — 18 to 30 — whose particular needs beyond the physical can often be overlooked. These issues range from choosing a…